Nine (26%) patients in combination group and 15 (35%) patients in lamivudine group had peak ALT more than 10 times upper limit of normal at biochemical relapse (P = 0. 59).

• 两组相比无显著性差异(P=0.；64)。 9例联合治疗患者(占26%25)和15例(占35%25)拉米夫定治疗患者出现ALT超过正常值上限的10倍。